THURSDAY | OCTOBER 15, 2020
|
|
ASIPP® and SIPMS Sends Comment Letters on Physician and ASC & HOPD 2021 Fee Schedules to CMS
|
|
Last week ASIPP and SIPMS sent two comment letters to CMS - one on the 2021 Physician Fee Schedule and the other addressing the ASC &HOPD 2021 Fee Schedule. |
|
Latest $20 Billion Round Of CARES Act Physician Relief Now Open |
|
What’s the news: The Department of Health and Human Services (HHS) is disbursing another $20 billion in financial relief for physician practices and other health care delivery organizations and clinicians that is part of the Coronavirus Aid, Relief and Economic Security (CARES) Act.
Under this phase three general distribution allocation, physicians who have already received CARES Act Provider Relief Fund payments may apply for additional funding to help compensate for financial losses and changes in operating expenses caused by the coronavirus. Previously ineligible physicians, such as those who began practicing in 2020, are also eligible to apply for the funding available in this round.
|
|
FDA OKs First Monoclonal Antibody Ebola Tx |
|
Three-drug cocktail was one of two Ebola therapies to
reduce 28-day mortality
|
|
Inmazeb, administered via infusion, was approved for adult and pediatric patients based on the results of the PALM trial, which examined multiple Ebola therapeutics.
Of the 154 patients in the trial who received Inmazeb (previously called REGN-EB3 after its manufacturer, Regeneron Pharmaceuticals), 33.8% died after 28 days compared to 51% of the 153 patients receiving control medication.
|
|
Recordings of Virtual Annual Meeting Now Available |
|
If you missed the ASIPP Virtual Annual Meeting in September, you may still register to view the recorded version. All sessions from the September 4-6, 2020 meeting are available through June 2021 for a reduced fee. On-demand registration also provides access to all of the great re|sources available in the exhibit hall.
A significantly reduced add-on fee is available for those who pre-registered for the live meeting, as well as for fellows, residents and medical students. Registrations for those who did not pre-register for the live meeting will also be accepted.
CME Statement
Recorded sessions for this meeting are not eligible for CME credits.
|
|
Role of Intravenous Acetaminophen in Reducing Opioid Consumption After Surgery |
|
The opioid-sparing effect of acetaminophen was more common in single-dose cohorts than in multidose cohorts.
Intravenous acetaminophen is not an effective option for reducing opioid consumption after surgical intervention, compared with other analgesic agents, according to study results published in Pain Medicine.
Intravenous acetaminophen is approved for the management of moderate to severe pain with adjunctive opioid analgesics, but limited data are available on the opioid-sparing effect of intravenous acetaminophen after various surgical interventions. The objective of the current systematic review was to determine the opioid-sparing effect of intravenous acetaminophen following various types of surgical intervention.
|
|
Competition Declined in Majority of Health Insurance Markets Where it was Most Scarce |
|
AMA study finds increasingly limited health insurance options for patients in highly concentrated |
|
Between 2014 and 2019, the share of markets that were highly concentrated increased from 71% to 74%. Moreover, more than half (52%) of the markets that were highly concentrated in 2014 grew even more concentrated by 2019.
“For many of the 70 million Americans who live in highly concentrated health insurance markets, a lack of competition is a problem that keeps getting worse as consumers have more limited health insurance options to choose,” said AMA President Susan R. Bailey, M.D. “The AMA strongly encourages a dialogue among regulators, policymakers, lawmakers, and others about the need for a better, more open and competitive marketplace to benefit patients and the physicians who care for them.”
|
|
Competition in Health Insurance: A Comprehensive Study of U.S. Markets is a vital element of AMA’s continued antitrust advocacy to protect patients and physicians from competitive harm. Health insurance market concentration will continue to be a vital issue of public policy for the AMA, the federation of medicine, and the nation’s physicians and patients.
|
|
Course Directors: (left to right) Laxmaiah Manchikanti, MD; Amol Soin, MD;
Sudhir Diwan, MD; Sheri Albers, DO; Harold Cordner, MD
|
|
This in-depth Regenerative Medicine Review Course meets the criteria for didactics when the Cadaver Workshops resume. It serves as curriculum for the ABIPP Competency Examination in Regenerative Medicine written exam and adds qualifications towards competency certification.
This review course is intended to present interventional pain management specialists, nurses, and other healthcare providers an in-depth review of multiple areas in
Regenerative Medicine.
|
|
|
|
Course Title:
Comprehensive Review Course Documentation,
Coding, Compliance, and Practice Management
Date:
October 24-25, 2020
Credit:
21 AMA PRA Category 1 Credits™
Course Directors:
Laxmaiah Manchikanti, MD; Amol Soin, MD; Hans Hansen, MD
|
|
|
|
Course Title:
Pain Medicine and Interventional Pain Management Comprehensive Review Course
Date:
November 6-8 and 13-15, 2020
Credit:
51 AMA PRA Category 1 Credits™
Course Information:
This course, promoted in collaboration with PainExam.com and PainCast, offers preparation for ABMS Pain Medicine Board Examination, Controlled Substance Management Competency, ABIPP-Pathway, and the ABIPP Board Examination
|
|
Imaging Review Course
Only purchase if you attended the live webinar course
|
|
Controlled Substance Management
Only purchase if you attended the live webinar course
|
|
Board Review Course
Only purchase if you attended the live webinar course
|
|
Documentation, Coding, Compliance, and
Practice Management
Only purchase if you attended the live webinar course
|
|
Controlled Substance Management
Only purchase if you attended the live webinar course
|
|
Board Review Course
Only purchase if you attended the live webinar course
|
|
ABIPP Recognizes Your Knowledge and Expertise
The American Board of Interventional Pain Physicians (ABIPP) has developed certification programs that recognize accepted levels of knowledge and expertise in the interventional pain management profession, with the goal of improved patient care. Hundreds of qualified physicians have made the commitment to become ABIPP certified.
ABIPP now offers the only competency
certification program for regenerative medicine.
For complete information about the examination requirements and to obtain an application packet, visit www.abipp.org or call 270-554-9412 x4217 or by email at summer@asipp.org.
|
|
TESTS OFFERED
ABIPP Part I - Theoretical written exam - TBD
ABIPP Part II - Oral and Hands-on practical exam - TBD
ABIPP Competency Exam - includes written, oral, and hands-on practical examinations TBD
Combined CSM/CCPM Exam for ABIPP Path – TBD
Competency Exam in Controlled Substance Management – TBD
Competency Exam in Coding, Compliance, and Practice Management - TBD
Regenerative Medicine Competency Exam - includes written, oral, and hands-on practical examinations – TBD
|
|
|
CDC Now Acknowledges Airborne Transmission of COVID-19 |
|
HealthDay News — Infection with the new coronavirus can occur through airborne transmission between people farther than 6 feet apart, the U.S. Centers for Disease Control and Prevention acknowledged in an update to its website on Monday.
The agency said this is especially true in enclosed spaces with inadequate ventilation.
The CDC update comes in response to growing evidence that coronavirus infection can occur through tiny droplets and particles that float in the air for minutes or even hours.
|
|
COVID-19 Antibodies Raise Unanswered Clinical Questions |
|
While monoclonal antibody treatment may hold promise for COVID-19, its clinical benefit has yet to be proven, said experts from the Infectious Diseases Society of America (IDSA).
In a media briefing, IDSA experts discussed that while manufacturers of monoclonal antibody treatment, Regeneron and Eli Lilly, both applied for emergency use authorization (EUA) from the FDA to treat COVID-19, the data on both so far have yet to demonstrate any impact on patient care.
|
|
Feds Seeks to Punish Center for Demoting 'Racist' Fellowship Director |
|
The federal government cracked down on two universities this week, apparently acting on Trump administration efforts against what it sees as discrimination in favor of certain minority groups.
The U.S. Department of Education opened an investigation into the University of Pittsburgh over demoting a electrophysiology fellowship director related to his anti-affirmative action paper.
|
|
ASIPP® Partners with Fedora Billing And Revenue Cycle Management Company
|
|
ASIPP is now able to offer unique benefits for revenue cycle management with billing, etc.
Fedora is a company known to many of our board members and others. ASIPP® has reached an agreement with Fedora to provide exclusive discounts on billing or revenue cycle management that will decrease practice costs and promote growth, or at least stop deterioration. It is not just a billing company; they streamline the billing and receivable process and constantly update payor regulations keeping your practice up to on date on a daily basis.
Some of the ASIPP® Billing Program highlights are below:
Up to 50% savings for ASIPP® members for their billing or revenue cycle management for their offices and surgery centers:
- Expertise in interventional pain management billing for all types of services
- 99% Clearing House Rate
- 95% First-Time Claim Passage
- 23.4 Average Days in A/R
- Eligibility and Benefits Verification
- Pre-Certification/Prior Authorization
- Denials and A/R Management
|
|
Join The Group Purchasing
Organization Today
|
|
ASIPP® has formed a partnership with Henry Schein and PedsPal, a national GPO that has a successful history of negotiating better prices on medical supplies and creating value added services for the independent physician. Working with MedAssets, PedsPal provides excellent pricing on products like contrast media that alleviate some of the financial pressures you experience today. While the cost of contrast media has skyrocketed due to the single dose vial issue, because we have partnered with Henry Schein, this could enable you to purchase Omnipaque 240mg/50mL for slightly above $4.50.
Click on “view our discounted supplier prices” (Username: ASIPPmember and Password: Save) or click on the words "join for free now" and begin saving today!
|
|
Essentials of Regenerative Medicine in Interventional
Pain Management
|
|
|
|
Essentials of Regenerative Medicine in Interventional Pain Management is a book to bring concise, collective, and comprehensive information to interventional pain physicians practicing regenerative medicine in managing chronic pain. Regenerative medicine is an integral part of interventional pain management within the definitions of interventional pain management and interventional techniques.
Each chapter contains an introduction of the subject, historical context,pathophysiology, applicability of regenerative medicine with its evidence base, indications, anatomy, technical aspects, complications, and precautions for each topic when available and applicable. This comprehensive book consists of 35 chapters, more than 350 figures, and 50 tables.
|
|
| ORDER | Essentials of Regenerative Medicine in IPM
|
|
Control Your Waiting Room TV
Customized waiting room TV exclusively for ASIPP® members. Create your own ad-free television broadcasts using our videos, custom informational slides and your own YouTube videos. Even add local weather reports, news and live messages.
|
|
|
In addition, PainExam has now collaborated with ASIPP and offer 2 new programs:
|
|
|
|
|
2020 12th Annual Scientific
Meeting
|
|
|
|
|
|
|
|
|
|
